Basic Klaricid Information

• INN (International Nonproprietary Name): Clarithromycin
• Brand Names Available In United Kingdom: Klacid; generic clarithromycin formulations (immediate‑release and extended‑release) — Biaxin and Mavid listed internationally but Klacid and generics are the main names referenced for Europe including the UK.
• ATC Code: J01FA09
• Forms & Dosages: Immediate‑release tablets 250 mg and 500 mg; extended‑release 500 mg tablets; granules for oral suspension 125 mg/5 mL and 250 mg/5 mL for reconstitution.
• Manufacturers In United Kingdom: Not specified; European/global suppliers include Abbott, Mylan, Teva and original innovator AbbVie (Biaxin) with many generics available.
• Registration Status In United Kingdom: Not specified.
• OTC / Rx Classification: Prescription (Rx Only) in nearly all countries.

Latest Research Highlights (UK & EU, 2022–2025)

Are macrolide resistance trends changing how we use clarithromycin in the UK?

Surveillance reports from UKHSA and ECDC between 2022 and 2025 record rising macrolide resistance among common respiratory pathogens, with notable impact on Streptococcus pneumoniae and Helicobacter pylori.

That trend has reduced the likely efficacy of clarithromycin‑based triple therapy for H. pylori in many regions where resistance has risen above recommended thresholds.

Randomised and observational studies across Europe compared clarithromycin with azithromycin and amoxicillin‑based regimens for community respiratory infections and found variable results linked to local resistance prevalence.

Where macrolide susceptibility remains low, clarithromycin retains symptomatic benefit for bronchitis and community respiratory infections.

For H. pylori, trials and treatment audits confirm diminished eradication rates when clarithromycin resistance exceeds about 15–20%, prompting guideline changes in affected areas.

MHRA safety reviews and Yellow Card analyses between 2022 and 2025 highlighted rare but important risks: QT prolongation, hepatic reactions and serious drug–drug interactions via CYP3A4.

Yellow Card data specifically flagged colchicine and statin co‑prescribing as situations with higher risk for severe adverse outcomes.

• Takeaway: macrolide surveillance shows regional heterogeneity — local susceptibility should guide clarithromycin use.
• Takeaway: clarithromycin retains symptomatic value for respiratory infections when resistance is low.
• Takeaway: avoid clarithromycin as first‑line for H. pylori where local resistance exceeds 15–20%.
• Takeaway: monitor for QT risk, hepatic dysfunction and CYP3A4 interactions; report suspected ADRs to Yellow Card.

Clinical Effectiveness In The UK (NHS Outcomes & Patient Reports)

Will clarithromycin work for my chest infection?

Real‑world NHS audit data and patient reports show clarithromycin remains effective for many community respiratory and some skin infections when local susceptibility supports its use.

Typical adult dosing in these audits was 250–500 mg every 12 hours, with symptom improvement reported within 48–72 hours in many patients for community‑acquired pneumonia and exacerbations of chronic bronchitis.

Treatment failures were more frequent where macrolide resistance was documented or suspected, especially for H. pylori eradication where clarithromycin‑containing triple therapy underperforms if resistance exceeds around 15–20%.

Patient feedback via NHS forums and primary‑care follow‑up highlights tolerability issues that can affect adherence: metallic taste, nausea and diarrhoea are the commonest complaints.

Adherence problems were associated with early discontinuation in some cases, particularly when taste disturbance or gastrointestinal upset was prominent.

Indications & Expanded Uses (MHRA‑Approved And Off‑Label Practices)

What do NHS formularies and MHRA list clarithromycin for?

MHRA and standard formularies list clarithromycin for respiratory tract infections, skin and soft‑tissue infections, H. pylori as part of combination therapy, and mycobacterial infections such as MAC prophylaxis or treatment in immunocompromised patients.

Off‑label use happens in some ENT and dermatology settings for chronic suppurative conditions when alternatives have failed and specialist microbiology input supports it.

In secondary care, intravenous clarithromycin may be used where oral administration is unsuitable, although IV availability varies between trusts.

Paediatric practice uses suspension formulations dosed by mg/kg (7.5 mg/kg every 12 hours up to 500 mg per dose).

MHRA‑Approved Uses

Community‑acquired pneumonia, acute bronchitis, acute maxillary sinusitis, skin/soft‑tissue infections, H. pylori as part of triple therapy, MAC in HIV when indicated.

Common Off‑Label Uses

Chronic ENT infections and selected dermatology indications after specialist review and stewardship input.

Prescriber Checklist:

• Confirm diagnosis and consider culture/susceptibility where possible.
• Check allergy history, prior clarithromycin‑related hepatic events and QT risk.
• Review current medications for CYP3A4 interactions and avoid colchicine co‑prescribing in vulnerable patients.

Composition & Brand Landscape (UK Brands, Generics, Formulations)

Which packaging and brands will patients see at the pharmacy?

Clarithromycin (INN) is available as branded Klacid in Europe and under multiple generic names across the UK market.

International brands include Biaxin/Biaxin XL and Mavid, but the UK supply generally references Klacid and generics from major manufacturers.

Storage Notes:

• Tablets: store below 25°C, protect from light and moisture.
• Reconstituted suspension: refrigerate 2–8°C and discard after 14 days.

Contraindications & Special Precautions (High‑Risk Groups)

Who must not take clarithromycin or needs special monitoring?

Absolute contraindications include hypersensitivity to clarithromycin or other macrolides and a history of clarithromycin‑related cholestatic jaundice or hepatic dysfunction.

Co‑administration with colchicine in patients with hepatic or renal impairment is contraindicated.

Use caution in patients with known arrhythmias or risk factors for QT prolongation and with severe hepatic dysfunction where clarithromycin is generally avoided.

Renal impairment with CrCl <30 mL/min requires dose reduction or interval extension.

Pregnancy and breastfeeding: specialist input is advised and treatment decisions should be based on individual risk–benefit assessment.

Patient Advice Highlights:

• Assess polypharmacy and interactions in elderly patients.
• Advise patients to report dizziness, palpitations or jaundice promptly.

Dosage Guidelines (NHS‑Recommended Regimens & Adjustments)

What dose should patients take for common infections?

Adults: typical dosing is 250–500 mg every 12 hours for 7–14 days for many respiratory and skin infections, with acute maxillary sinusitis often prescribed as 500 mg twice daily for 14 days.

H. pylori regimens commonly use 500 mg twice daily with amoxicillin and a proton pump inhibitor for 7–14 days.

Paediatric dosing: 7.5 mg/kg every 12 hours up to a maximum of 500 mg per dose, using reconstituted suspension.

Renal impairment: if CrCl <30 mL/min, halve the dose or double the dosing interval.

For MAC in HIV, clarithromycin 500 mg twice daily is used in combination with other agents as per specialist protocols.

Missed Dose Advice: take as soon as remembered unless next dose is due; do not double up.

Interactions Overview (Food, Drink, Medicines; MHRA Yellow Card Data)

Which medicines and habits interact with clarithromycin?

Clarithromycin is a CYP3A4 inhibitor and can raise plasma concentrations of many co‑prescribed drugs including simvastatin, certain benzodiazepines, some antiarrhythmics and colchicine.

Yellow Card reports emphasise severe adverse outcomes when clarithromycin is combined with colchicine or QT‑prolonging drugs, and note statin interactions as clinically important.

Alcohol does not have a direct pharmacokinetic interaction but can increase GI upset and liver risk, so advise moderation.

Grapefruit is not strongly documented against clarithromycin specifically, but caution is sensible with CYP3A4 substrate medicines.

Pharmacy Practice Tip: run an electronic interaction check and document counselling; flag Yellow Card‑reportable events.

Cultural Perceptions & Patient Habits (UK Patient Insights)

How do UK patients approach antibiotics for chest infections?

Many patients consult pharmacists first or use NHS 111 and the NHS App before contacting their GP for respiratory symptoms.

Online forums such as Patient.info and Mumsnet show mixed expectations: some still expect antibiotics for chest infections, while public stewardship campaigns have reduced inappropriate demand.

Pharmacist counselling at community chains or independent pharmacies remains a key cultural touchpoint for dosing advice and side‑effect management.

Electronic prescriptions and NHS App messaging are increasingly used to confirm dosing, send reminders and provide leaflets about side effects.

• Common Patient Concerns: "Will this upset my stomach?", "Can I drive while taking this?", "Is it safe in pregnancy?"
• Recommended Counselling Points: side effects, finish the course, interaction checks and when to reconsult (48–72 hours for worsening or no improvement).

Availability & Pricing Patterns (Boots, Lloyds, Superdrug; NHS Charges)

Where can clarithromycin be obtained and what does it cost?

Clarithromycin is prescription‑only in the UK and commonly dispensed by major chains such as Boots, LloydsPharmacy and Superdrug, as well as by independent community pharmacies and online prescribers that accept e‑prescriptions.

Generic clarithromycin is typically cheaper than branded Klacid or international Biaxin packs, and NHS formularies often favour generics where available.

Prescription charging differences across the UK affect out‑of‑pocket cost: England has a per‑item prescription charge while Scotland, Wales and Northern Ireland have different exemption schemes.

Purchase Note: In our online pharmacy, klaricid is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines & Prescribing Preferences (NHS Alternatives)

Which drugs do GPs choose instead of clarithromycin?

Common NHS alternatives include azithromycin, doxycycline, amoxicillin and amoxicillin–clavulanate depending on the infection and suspected pathogens.

Choice hinges on local resistance patterns, allergy history and drug interaction risk; clarithromycin is often chosen for penicillin‑allergic patients but its interaction profile can be limiting.

Decision Flow: consider local resistance, allergy status and drug interactions before selecting clarithromycin or an alternative such as doxycycline or azithromycin.

FAQ

Q: Can I drink alcohol on clarithromycin?

A: There is no specific prohibition, but alcohol can worsen gastrointestinal side effects and may increase liver risk; moderate intake and individual advice from a pharmacist is sensible.

Q: Is clarithromycin safe in pregnancy?

A: Use only if the prescriber and specialist judge the benefit to outweigh risk and after consulting MHRA/NICE guidance where appropriate.

Q: What should I do if I miss a dose?

A: Take it as soon as you remember unless the next dose is due soon; do not double the next dose.

Q: Should I stop if I get a metallic taste?

A: Taste disturbance is common and usually temporary; speak with a pharmacist or GP if it is severe or affecting ability to complete the course.

For further patient leaflets consult NHS.uk and MHRA resources.

Guidelines For Proper Use (UK Pharmacist Counselling & NHS Support)

How should pharmacists counsel patients who collect clarithromycin?

Confirm the indication, check for allergies and previous clarithromycin‑related hepatic reactions, and review the patient’s current medicine list for CYP3A4 substrates or QT‑prolonging medicines.

Explain dosing clearly, including paediatric suspension instructions and renal or hepatic dose adjustments when relevant.

Advise refrigeration of reconstituted suspension and to discard any unused product after 14 days.

Emphasise completing the full course and reconsulting if symptoms worsen or there is no improvement within 48–72 hours.

• Pharmacist Counselling Checklist: indication confirmation, allergy check, interaction review, dosing explanation, storage and discard instructions, Yellow Card reporting information.
• Action Steps: stop and seek medical review for signs of liver injury or arrhythmia; escalate care for breathing difficulty or severe rash.

Delivery Across United Kingdom